<DOC>
	<DOC>NCT01253902</DOC>
	<brief_summary>This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis of ocular hypertension or openangle glaucoma in at least 1 eye requiring treatment with an antiglaucoma/ocular hypertensive medication Best corrected visual acuity score of 20/100 or better in both eyes Females on birth control pills must be on same type of pill and dose for at least 3 month Use of Lumigan® 0.01%/Lumigan® RC, Lumigan®, Travatan® or Travatan Z® within 6 months History of or active ocular infection/inflammation (eg, uveitis) Punctal plug use Required use of ocular medications during the study other than study medication (intermittent use of certain types artificial tears acceptable) Intraocular surgery or glaucoma laser surgery in study eye(s) within 3 months History of corneal refractive laser surgery (eg, LASIK, LASEK) in study eye(s) Planned contact lens wear during study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>